Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

Shinzaburo Noguchi, Norikazu Masuda, Hiroji Iwata, Hirofumi Mukai, Jun Horiguchi, Puttisak Puttawibul, Vichien Srimuninnimit, Yutaka Tokuda, Katsumasa Kuroi, Hirotaka Iwase, Hideo Inaji, Shozo Ohsumi, Woo Chul Noh, Takahiro Nakayama, Shinji Ohno, Yoshiaki Rai, Byeongwoo Park, Ashok Panneerselvam, Mona El-Hashimy, Tetiana TaranTarek Sahmoud, Yoshinori Ito

Research output: Contribution to journalArticle

44 Citations (Scopus)

Abstract

Results: Of 143 Asian patients, 98 received EVE + EXE and 45 received PBO + EXE. Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41–0.94). Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33–0.50). Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients. The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients. Grade 1/2 interstitial lung disease occurred more frequently in Asian patients. Quality of life was similar between treatment arms in Asian patients.

Conclusion: Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles. This combination represents an improvement in the management of postmenopausal women with HR + /HER2 advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity.

Background: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR + ) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be influenced by ethnicity (Sekine et al. in Br J Cancer 99:1757–62, 2008). Safety and efficacy results from Asian versus non-Asian patients in BOLERO-2 are reported.

Methods: Patients were randomized (2:1) to 10 mg/day EVE + EXE or placebo (PBO) + EXE. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, response rate, clinical benefit rate, and safety.

Original languageEnglish
Pages (from-to)703-714
Number of pages12
JournalBreast Cancer
Volume21
Issue number6
DOIs
Publication statusPublished - 2014 Jan 1

Fingerprint

exemestane
Hormones
Breast Neoplasms
Disease-Free Survival
Placebos
Safety
letrozole
Everolimus

All Science Journal Classification (ASJC) codes

  • Oncology
  • Radiology Nuclear Medicine and imaging
  • Pharmacology (medical)

Cite this

Noguchi, Shinzaburo ; Masuda, Norikazu ; Iwata, Hiroji ; Mukai, Hirofumi ; Horiguchi, Jun ; Puttawibul, Puttisak ; Srimuninnimit, Vichien ; Tokuda, Yutaka ; Kuroi, Katsumasa ; Iwase, Hirotaka ; Inaji, Hideo ; Ohsumi, Shozo ; Noh, Woo Chul ; Nakayama, Takahiro ; Ohno, Shinji ; Rai, Yoshiaki ; Park, Byeongwoo ; Panneerselvam, Ashok ; El-Hashimy, Mona ; Taran, Tetiana ; Sahmoud, Tarek ; Ito, Yoshinori. / Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. In: Breast Cancer. 2014 ; Vol. 21, No. 6. pp. 703-714.
@article{cefdbdac71c84bd7a0051a258432d8c6,
title = "Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2",
abstract = "Results: Of 143 Asian patients, 98 received EVE + EXE and 45 received PBO + EXE. Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 {\%} (HR = 0.62; 95 {\%} CI, 0.41–0.94). Median PFS was also improved among non-Asian patients by 59 {\%} (HR = 0.41; 95 {\%} CI, 0.33–0.50). Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients. The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients. Grade 1/2 interstitial lung disease occurred more frequently in Asian patients. Quality of life was similar between treatment arms in Asian patients. Conclusion: Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles. This combination represents an improvement in the management of postmenopausal women with HR + /HER2 − advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity. Background: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR + ) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be influenced by ethnicity (Sekine et al. in Br J Cancer 99:1757–62, 2008). Safety and efficacy results from Asian versus non-Asian patients in BOLERO-2 are reported. Methods: Patients were randomized (2:1) to 10 mg/day EVE + EXE or placebo (PBO) + EXE. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, response rate, clinical benefit rate, and safety.",
author = "Shinzaburo Noguchi and Norikazu Masuda and Hiroji Iwata and Hirofumi Mukai and Jun Horiguchi and Puttisak Puttawibul and Vichien Srimuninnimit and Yutaka Tokuda and Katsumasa Kuroi and Hirotaka Iwase and Hideo Inaji and Shozo Ohsumi and Noh, {Woo Chul} and Takahiro Nakayama and Shinji Ohno and Yoshiaki Rai and Byeongwoo Park and Ashok Panneerselvam and Mona El-Hashimy and Tetiana Taran and Tarek Sahmoud and Yoshinori Ito",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s12282-013-0444-8",
language = "English",
volume = "21",
pages = "703--714",
journal = "Breast Cancer",
issn = "1340-6868",
publisher = "Springer Japan",
number = "6",

}

Noguchi, S, Masuda, N, Iwata, H, Mukai, H, Horiguchi, J, Puttawibul, P, Srimuninnimit, V, Tokuda, Y, Kuroi, K, Iwase, H, Inaji, H, Ohsumi, S, Noh, WC, Nakayama, T, Ohno, S, Rai, Y, Park, B, Panneerselvam, A, El-Hashimy, M, Taran, T, Sahmoud, T & Ito, Y 2014, 'Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2', Breast Cancer, vol. 21, no. 6, pp. 703-714. https://doi.org/10.1007/s12282-013-0444-8

Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2. / Noguchi, Shinzaburo; Masuda, Norikazu; Iwata, Hiroji; Mukai, Hirofumi; Horiguchi, Jun; Puttawibul, Puttisak; Srimuninnimit, Vichien; Tokuda, Yutaka; Kuroi, Katsumasa; Iwase, Hirotaka; Inaji, Hideo; Ohsumi, Shozo; Noh, Woo Chul; Nakayama, Takahiro; Ohno, Shinji; Rai, Yoshiaki; Park, Byeongwoo; Panneerselvam, Ashok; El-Hashimy, Mona; Taran, Tetiana; Sahmoud, Tarek; Ito, Yoshinori.

In: Breast Cancer, Vol. 21, No. 6, 01.01.2014, p. 703-714.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Efficacy of everolimus with exemestane versus exemestane alone in Asian patients with HER2-negative, hormone-receptor-positive breast cancer in BOLERO-2

AU - Noguchi, Shinzaburo

AU - Masuda, Norikazu

AU - Iwata, Hiroji

AU - Mukai, Hirofumi

AU - Horiguchi, Jun

AU - Puttawibul, Puttisak

AU - Srimuninnimit, Vichien

AU - Tokuda, Yutaka

AU - Kuroi, Katsumasa

AU - Iwase, Hirotaka

AU - Inaji, Hideo

AU - Ohsumi, Shozo

AU - Noh, Woo Chul

AU - Nakayama, Takahiro

AU - Ohno, Shinji

AU - Rai, Yoshiaki

AU - Park, Byeongwoo

AU - Panneerselvam, Ashok

AU - El-Hashimy, Mona

AU - Taran, Tetiana

AU - Sahmoud, Tarek

AU - Ito, Yoshinori

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Results: Of 143 Asian patients, 98 received EVE + EXE and 45 received PBO + EXE. Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41–0.94). Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33–0.50). Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients. The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients. Grade 1/2 interstitial lung disease occurred more frequently in Asian patients. Quality of life was similar between treatment arms in Asian patients. Conclusion: Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles. This combination represents an improvement in the management of postmenopausal women with HR + /HER2 − advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity. Background: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR + ) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be influenced by ethnicity (Sekine et al. in Br J Cancer 99:1757–62, 2008). Safety and efficacy results from Asian versus non-Asian patients in BOLERO-2 are reported. Methods: Patients were randomized (2:1) to 10 mg/day EVE + EXE or placebo (PBO) + EXE. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, response rate, clinical benefit rate, and safety.

AB - Results: Of 143 Asian patients, 98 received EVE + EXE and 45 received PBO + EXE. Treatment with EVE + EXE significantly improved median PFS versus PBO + EXE among Asian patients by 38 % (HR = 0.62; 95 % CI, 0.41–0.94). Median PFS was also improved among non-Asian patients by 59 % (HR = 0.41; 95 % CI, 0.33–0.50). Median PFS duration among EVE-treated Asian patients was 8.48 versus 4.14 months for PBO + EXE, and 7.33 versus 2.83 months, respectively, in non-Asian patients. The most common grade 3/4 adverse events (stomatitis, anemia, elevated liver enzymes, hyperglycemia, and dyspnea) occurred at similar frequencies in Asian and non-Asian patients. Grade 1/2 interstitial lung disease occurred more frequently in Asian patients. Quality of life was similar between treatment arms in Asian patients. Conclusion: Adding EVE to EXE provided substantial clinical benefit in both Asian and non-Asian patients with similar safety profiles. This combination represents an improvement in the management of postmenopausal women with HR + /HER2 − advanced breast cancer progressing on nonsteroidal aromatase inhibitors, regardless of ethnicity. Background: The addition of mTOR inhibitor everolimus (EVE) to exemestane (EXE) was evaluated in an international, phase 3 study (BOLERO-2) in patients with hormone-receptor-positive (HR + ) breast cancer refractory to letrozole or anastrozole. The safety and efficacy of anticancer treatments may be influenced by ethnicity (Sekine et al. in Br J Cancer 99:1757–62, 2008). Safety and efficacy results from Asian versus non-Asian patients in BOLERO-2 are reported. Methods: Patients were randomized (2:1) to 10 mg/day EVE + EXE or placebo (PBO) + EXE. Primary endpoint was progression-free survival (PFS). Secondary endpoints included overall survival, response rate, clinical benefit rate, and safety.

UR - http://www.scopus.com/inward/record.url?scp=84873499330&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84873499330&partnerID=8YFLogxK

U2 - 10.1007/s12282-013-0444-8

DO - 10.1007/s12282-013-0444-8

M3 - Article

C2 - 23404211

AN - SCOPUS:84873499330

VL - 21

SP - 703

EP - 714

JO - Breast Cancer

JF - Breast Cancer

SN - 1340-6868

IS - 6

ER -